


Virtual Clinical Trials Session 1: Opportunities to Improve Clinical Trials









Craig Lipset

@craiglipsetNovember 28 2018National Academies

Centralization Followed by Decentralization...







Centralization Followed by Decentralization...

Centralize:


- Investigator
- Coordinator
- Labs
- Diagnostic Reads
- IRBs


Decentralize Participation:

- Improve Access
- Reduce Burden
- Improve Representation



Industry Evolution Since the Pfizer REMOTE Trial







FierceBiotech








Destination for Virtual Trials







Virtual Trials: Primary Obstacles

- Legal/Regulatory variability (by state, by country)
- Ensure healthcare providers are engaged (rather than marginalized)
- Robust efficacy & safety endpoints that may be captured with confidence agnostic to location
















Roadmap to Improving Trial Efficiency

Near-Term

- Anticipate cost-neutral for direct costs
- Location is shifted, but procedures and staff-time may be minimally changed
- Increased cost where study team capabilities are added but none replaced
- Potential indirect cost savings associated with reduced speed (without compromising quality)

Long-Term

- Potential for savings over long-term
 - Use existing consumer technologies
 - Replace (rather than add) study team capabilities
 - Better embed research participation within healthcare settings

